Post-approval observational Study to assess Clinical Effectiveness andSafety of Nicorandil as initial- line adjuvant therapy in MVA and ANOCA - NI

Torrent Pharmaceutical Ltd0 个研究点目标入组 0 人开始时间: 待定最近更新: 2024年8月19日

试验速览

暂无简介。

•Male or female patients more than 18 years of age
•Stable CAD cases with effort or exertional Angina
•Stable CAD with effort Angina who have undergone CCTA or Angiography to delineate coronary anatomy for non obstructive CAD

•Trop T more than 0 point 07 nano gram per ml and ECG changes with ST deviation more than 0 point 05 mV that require PCI
•Unstable or uncontrolled cases of CAD with Hypertension or signs of acute MI with blood pressure less than 100mmhg
•Cardiac shock
•Aortic dissection
•History of myocardial infarction or percutaneous coronary intervention or coronary artery bypass grafting less than 1 month
•Contraindicated or intolerable to nicorandil
•Patients on background use of Long acting nitrates
•Pregnant or lactation period
•Patients with an estimated survival time of less than 1 year

发起方

Torrent Pharmaceutical Ltd